Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "AP"

8349 News Found

SMS Pharmaceutical's associate company receives FDA approval for reformulated Ranitidine
Drug Approval | November 27, 2025

SMS Pharmaceutical's associate company receives FDA approval for reformulated Ranitidine

The approval by the US FDA comes after extensive safety testing and manufacturing improvements


Medtronic launches first 'intelligent' circular stapler to boost surgical precision, reduce leaks
News | November 27, 2025

Medtronic launches first 'intelligent' circular stapler to boost surgical precision, reduce leaks

The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk


Owlet taps OpenSynergy’s bluetooth tech to power next-gen baby monitor
Medical Device | November 27, 2025

Owlet taps OpenSynergy’s bluetooth tech to power next-gen baby monitor

Owlet’s push comes as parents demand smarter, more dependable nursery tech


Otsuka files FDA application for first-in-class ADHD drug
Clinical Trials | November 27, 2025

Otsuka files FDA application for first-in-class ADHD drug

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor


NHS’s breakthrough leukaemia therapy set to transform lives in UK
Clinical Trials | November 27, 2025

NHS’s breakthrough leukaemia therapy set to transform lives in UK

Clinical trials found that 77% of patients went into remission after receiving obe-cel


India becomes first country to approve STIMULAN Rapid Cure with antifungals
Medical Device | November 26, 2025

India becomes first country to approve STIMULAN Rapid Cure with antifungals

Surgical site infections and antimicrobial resistance remain major challenges globally


EU clears Bristol Myers Squibb’s CAR-T therapy Breyanzi for tough-to-treat Lymphoma
Drug Approval | November 25, 2025

EU clears Bristol Myers Squibb’s CAR-T therapy Breyanzi for tough-to-treat Lymphoma

The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries